BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Müllauer L, Mechtersheimer G, von Deimling A. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120:e28-34. [PMID: 22859608 DOI: 10.1182/blood-2012-06-429597] [Cited by in Crossref: 158] [Cited by in F6Publishing: 136] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 2015;5:64-71. [PMID: 25324352 DOI: 10.1158/2159-8290.CD-14-0742] [Cited by in Crossref: 91] [Cited by in F6Publishing: 49] [Article Influence: 11.4] [Reference Citation Analysis]
2 Koelsche C, Sahm F, Paulus W, Mittelbronn M, Giangaspero F, Antonelli M, Meyer J, Lasitschka F, von Deimling A, Reuss D. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol 2014;40:337-44. [PMID: 23822828 DOI: 10.1111/nan.12072] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
3 Sasaki Y, Guo Y, Arakawa F, Miyoshi H, Yoshida N, Koga Y, Nakashima K, Kurita D, Niino D, Seto M, Ohshima K. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan. Hematol Oncol 2017;35:329-34. [PMID: 27041734 DOI: 10.1002/hon.2293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
4 Schwentner R, Jug G, Kauer MO, Schnöller T, Waidhofer-Söllner P, Holter W, Hutter C. JAG2 signaling induces differentiation of CD14+ monocytes into Langerhans cell histiocytosis-like cells. J Leukoc Biol 2019;105:101-11. [PMID: 30296338 DOI: 10.1002/JLB.1A0318-098R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Adawi M, Bisharat B, Bowirrat A. Erdheim-Chester disease (ECD): Case report, clinical and basic investigations, and review of literature. Medicine (Baltimore) 2016;95:e5167. [PMID: 27759649 DOI: 10.1097/MD.0000000000005167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
6 Kim S, Choi MK, Han HS, Song H, Koh Y, Son S, Lee O, Lee JY, Lee KM, Lee KH, Kwon J. A Case of Pulmonary Langerhans Cell Sarcoma Simultaneously Diagnosed with Cutaneous Langerhans Cell Histiocytosis Studied by Whole-Exome Sequencing. Acta Haematol 2017;138:24-30. [DOI: 10.1159/000476026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Mitchell J, Kvedaraite E, von Bahr Greenwood T, Henter JI, Pellicci DG, Berzins SP, Kannourakis G. Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis. Sci Rep 2018;8:16506. [PMID: 30405183 DOI: 10.1038/s41598-018-34873-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
8 Allen CE, Kelly KM, Bollard CM. Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am 2015;62:139-65. [PMID: 25435117 DOI: 10.1016/j.pcl.2014.09.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
9 Obert J, Tazi A. [Pulmonary manifestations of Langerhans cell histiocytosis]. Rev Mal Respir 2015;32:850-66. [PMID: 26003197 DOI: 10.1016/j.rmr.2015.01.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol. 2016;52:61-67. [PMID: 26980021 DOI: 10.1016/j.humpath.2015.12.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
11 Yuan X, Tang M, Sheng Q, Zhu X, Zhang Q. Swelling of bilateral parotid glands: An unusual symptom of multisystem Langerhans cell histiocytosis. SAGE Open Med Case Rep 2014;2:2050313X14531220. [PMID: 27489645 DOI: 10.1177/2050313X14531220] [Reference Citation Analysis]
12 Huang H, Lu T, Sun Y, Li S, Li J, Xu K, Feng RE, Xu ZJ. Association between clinicopathologic characteristics and BRAFV600E expression in Chinese patients with Langerhans cell histiocytosis. Thorac Cancer 2019;10:1984-92. [PMID: 31441596 DOI: 10.1111/1759-7714.13179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Mitchell J, Kelly J, Kvedaraite E, von Bahr Greenwood T, Henter J, Pellicci DG, Berzins SP, Kannourakis G. Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity. Clinical Immunology 2020;215:108418. [DOI: 10.1016/j.clim.2020.108418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Kobayashi T, Koga Y, Ishimura M, Nakashima K, Kato W, Ono H, Sonoda M, Eguchi K, Fukano R, Honjo S, Oda Y, Ohga S. Fever and Skin Involvement at Diagnosis Predicting the Intractable Langerhans Cell Histiocytosis: 40 Case-Series in a Single Center. Journal of Pediatric Hematology/Oncology 2018;40:e148-53. [DOI: 10.1097/mph.0000000000001080] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Arceci RJ. Dendritic Cell Disorders: Matters of Lineage and Clinical Drug Testing in Rare Diseases. JCO 2015;33:383-5. [DOI: 10.1200/jco.2014.58.9804] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Si YC, Liu Q, Hou HJ, Huang P. Multifocal eosinophilic granuloma of the jaws with long-term follow-up: a case report. Hua Xi Kou Qiang Yi Xue Za Zhi 2021;39:355-61. [PMID: 34041887 DOI: 10.7518/hxkq.2021.03.017] [Reference Citation Analysis]
17 Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015;54:361-8. [PMID: 25899310 DOI: 10.1002/gcc.22247] [Cited by in Crossref: 120] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
18 Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 2015;169:3-13. [PMID: 25430560 DOI: 10.1111/bjh.13247] [Cited by in Crossref: 96] [Cited by in F6Publishing: 74] [Article Influence: 12.0] [Reference Citation Analysis]
19 Wei R, Wang Z, Li X, Shu Y, Fu B. Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis. Biomed Rep 2013;1:365-8. [PMID: 24648950 DOI: 10.3892/br.2013.62] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
20 Quispel WT, Stegehuis-Kamp JA, Santos SJ, Egeler RM, van Halteren AG. Activated Conventional T-Cells Are Present in Langerhans Cell Histiocytosis Lesions Despite the Presence of Immune Suppressive Cytokines. J Interferon Cytokine Res 2015;35:831-9. [PMID: 26381039 DOI: 10.1089/jir.2014.0190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
21 Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition. Hematology 2015;2015:565-70. [DOI: 10.1182/asheducation-2015.1.565] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
22 Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495-1500. [PMID: 23258922 DOI: 10.1182/blood-2012-07-446286] [Cited by in Crossref: 344] [Cited by in F6Publishing: 297] [Article Influence: 34.4] [Reference Citation Analysis]
23 Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol 2014;122:48-58. [PMID: 24039206 DOI: 10.1002/cncy.21352] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
24 Mourah S, How-Kit A, Meignin V, Gossot D, Lorillon G, Bugnet E, Mauger F, Lebbe C, Chevret S, Tost J, Tazi A. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J. 2016;47:1785-1796. [PMID: 27076591 DOI: 10.1183/13993003.01677-2015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 9.7] [Reference Citation Analysis]
25 Cavalli G, Dagna L, Biavasco R, Villa A, Doglioni C, Ferrero E, Ferrarini M. Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer. J Leukoc Biol 2020;108:591-9. [PMID: 32056262 DOI: 10.1002/JLB.3MR0120-203RR] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bedran NR, Carlos R, de Andrade BAB, Bueno APS, Romañach MJ, Milito CB. Clinicopathological and Immunohistochemical Study of Head and Neck Langerhans Cell Histiocytosis from Latin America. Head Neck Pathol 2018;12:431-9. [PMID: 29164473 DOI: 10.1007/s12105-017-0867-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
27 Siegelin MD. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer? Cancer Lett 2013;333:133-46. [PMID: 23376257 DOI: 10.1016/j.canlet.2013.01.045] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
28 Dietel M, Jöhrens K, Laffert M, Hummel M, Bläker H, Müller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2013;20:211-21. [PMID: 23492822 DOI: 10.1038/cgt.2013.13] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
29 Phan TDA, Phung BG, Duong TT, Hoang VA, Ngo DQ, Trinh NDT, Tran TT. A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children. J Pathol Transl Med 2021;55:112-7. [PMID: 33494131 DOI: 10.4132/jptm.2020.11.30] [Reference Citation Analysis]
30 Duan MH, Han X, Li J, Zhang W, Zhu TN, Han B, Zhuang JL, Wang SJ, Cao XX, Cai HC, Chen M, Yang C, Zhou DB. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study. Leuk Res 2016;42:43-6. [PMID: 26859782 DOI: 10.1016/j.leukres.2016.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
31 Varga E, Korom I, Polyánka H, Szabó K, Széll M, Baltás E, Bata-csörgő Z, Kemény L, Oláh J. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis. J Eur Acad Dermatol Venereol 2015;29:1205-11. [DOI: 10.1111/jdv.12792] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
32 Rossi ED, Martini M, Bizzarro T, Schmitt F, Longatto-Filho A, Larocca LM. Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. Oncotarget 2017;8:3746-60. [PMID: 27738305 DOI: 10.18632/oncotarget.12564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Selway JL, Harikumar PE, Chu A, Langlands K. Genetic homogeneity of adult Langerhans cell histiocytosis lesions: Insights from BRAF V600E mutations in adult populations. Oncol Lett. 2017;14:4449-4454. [PMID: 29085441 DOI: 10.3892/ol.2017.6774] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
34 Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014;24:858-66. [PMID: 24417277 DOI: 10.1089/thy.2013.0302] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
35 Rollins BJ. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am 2015;29:839-51. [PMID: 26461146 DOI: 10.1016/j.hoc.2015.06.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
36 Dinges HC, Capper D, Ritz O, Brüderlein S, Marienfeld R, von Deimling A, Möller P, Lennerz JK. Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol 2015;23:382-8. [PMID: 25611237 DOI: 10.1097/PAI.0000000000000092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Elia D, Torre O, Cassandro R, Caminati A, Harari S. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26:351-356. [PMID: 25899682 DOI: 10.1016/j.ejim.2015.04.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
38 Bi L, Sun B, Lu Z, Shi Z, Wang D, Zhu Z. Langerhans cell histiocytosis with multisystem involvement in an infant: A case report. Exp Ther Med 2015;9:2137-40. [PMID: 26136948 DOI: 10.3892/etm.2015.2396] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
39 Harikumar PE, Selway JL, Chu A, Langlands K. Collagen remodeling and peripheral immune cell recruitment characterizes the cutaneous Langerhans cell histiocytosis microenvironment. Int J Dermatol 2015;54:e7-13. [PMID: 24602014 DOI: 10.1111/ijd.12375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Suh JK, Kang S, Kim H, Im HJ, Koh KN. Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis. Blood Res 2021;56:S65-9. [PMID: 33935037 DOI: 10.5045/br.2021.2021013] [Reference Citation Analysis]
41 Zhang C, Gao J, He J, Liu C, Lv X, Yin X, Deng Y, Lu Z, Tian Z. Regulatory T-cell expansion in oral and maxillofacial Langerhans cell histiocytosis. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:547-56. [PMID: 32988807 DOI: 10.1016/j.oooo.2020.08.005] [Reference Citation Analysis]
42 Straccia P, Brunelli C, Rossi ED, Lanza P, Martini M, Musarra T, Lombardi CP, Pontecorvi A, Fadda G. The immunocytochemical expression of VE ‐1 ( BRAF V600E‐related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid‐based cytology. Cytopathology 2019;30:460-7. [DOI: 10.1111/cyt.12690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
43 Breton Q, Plouhinec H, Prunier-Mirebeau D, Boisselier B, Michalak S, Menei P, Rousseau A. BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors. Brain Behav 2017;7:e00641. [PMID: 28293477 DOI: 10.1002/brb3.641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
44 Böttcher JP, Zelenay S, Rogers NC, Helft J, Schraml BU, Reis e Sousa C. Oncogenic Transformation of Dendritic Cells and Their Precursors Leads to Rapid Cancer Development in Mice. J Immunol 2015;195:5066-76. [PMID: 26459350 DOI: 10.4049/jimmunol.1500889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Aguirre LE, Schwartz I, Chapman J, Larsen MF, Alencar A. Adult Langerhans cell histiocytosis presenting with multisystem involvement and sarcomatoid features: a case report. J Med Case Rep 2020;14:169. [PMID: 32979930 DOI: 10.1186/s13256-020-02460-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Feng S, Han L, Yue M, Zhong D, Cao J, Guo Y, Sun Y, Zhang H, Cao Z, Cui X, Liu R. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing. Orphanet J Rare Dis 2021;16:272. [PMID: 34116682 DOI: 10.1186/s13023-021-01912-3] [Reference Citation Analysis]
47 Yin J, Zhang F, Zhang H, Shen L, Li Q, Hu S, Tian Q, Bao Y, Jia W. Hand-Schüller-Christian disease and Erdheim-Chester disease: coexistence and discrepancy. Oncologist 2013;18:19-24. [PMID: 23299772 DOI: 10.1634/theoncologist.2012-0234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
48 Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovée JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 2014;123:3152-5. [PMID: 24652991 DOI: 10.1182/blood-2013-06-511139] [Cited by in Crossref: 121] [Cited by in F6Publishing: 104] [Article Influence: 15.1] [Reference Citation Analysis]
49 Park S, Lee EJ. Diagnosis and treatment of cystic lung disease. Korean J Intern Med 2017;32:229-38. [PMID: 28264540 DOI: 10.3904/kjim.2016.242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
50 Feng C, Li Y, Ke H, Peng X, Guo H, Zhan L, Xiong X, Weng W, Li J, Fang J. Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators. Front Oncol 2021;11:631682. [PMID: 34026610 DOI: 10.3389/fonc.2021.631682] [Reference Citation Analysis]
51 Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2015;10:99-109. [PMID: 24859797 DOI: 10.1007/s11523-014-0319-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
52 Chugh A, Kaur A, Kumar Patnana A, Kumar P, Chugh VK. Unisystem Langerhans cell histiocytosis in maxillofacial region in pediatrics: comprehensive and systematic review. Oral Maxillofac Surg 2021. [PMID: 33591444 DOI: 10.1007/s10006-021-00949-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Egeler RM, Katewa S, Leenen PJ, Beverley P, Collin M, Ginhoux F, Arceci RJ, Rollins BJ; for the Steering Committee of the Nikolas Symposium. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci: Egeler et al. Pediatr Blood Cancer 2016;63:1704-12. [DOI: 10.1002/pbc.26104] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
54 Wechsler J. Les histiocytoses : comment classer ces affections hétérogènes à fort tropisme cutané ? Annales de Dermatologie et de Vénéréologie 2013;140:79-82. [DOI: 10.1016/j.annder.2012.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Hogstad B, Berres ML, Chakraborty R, Tang J, Bigenwald C, Serasinghe M, Lim KPH, Lin H, Man TK, Remark R, Baxter S, Kana V, Jordan S, Karoulia Z, Kwan WH, Leboeuf M, Brandt E, Salmon H, McClain K, Poulikakos P, Chipuk J, Mulder WJM, Allen CE, Merad M. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 2018;215:319-36. [PMID: 29263218 DOI: 10.1084/jem.20161881] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
56 Akarca AU, Shende VH, Ramsay AD, Diss T, Pane-Foix M, Rizvi H, Calaminici MR, Grogan TM, Linch D, Marafioti T. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 2013;162:848-51. [PMID: 23848818 DOI: 10.1111/bjh.12429] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
57 Kobayashi M, Ando S, Kawamata T, Makiyama J, Yokoyama K, Imai Y, Tojo A. Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience. Int J Hematol 2020;112:185-92. [PMID: 32514929 DOI: 10.1007/s12185-020-02892-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition. Hematology 2015;2015:565-70. [DOI: 10.1182/asheducation.v2015.1.565.3919688] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
59 Mitchell J, Kannourakis G. Does CD1a Expression Influence T Cell Function in Patients With Langerhans Cell Histiocytosis? Front Immunol 2021;12:773598. [DOI: 10.3389/fimmu.2021.773598] [Reference Citation Analysis]
60 Machnicki MM, Stoklosa T. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53:77-83. [PMID: 24495477 DOI: 10.1016/j.bcmd.2014.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
61 Sengal A, Velazquez J, Hahne M, Burke TM, Abhyankar H, Reyes R, Olea W, Scull B, Eckstein OS, Bigenwald C, Bollard CM, Yu W, Merad M, McClain KL, Allen CE, Chakraborty R. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood 2021;137:1777-91. [PMID: 33075814 DOI: 10.1182/blood.2020005867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CC. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol 2017;30:734-44. [PMID: 28084334 DOI: 10.1038/modpathol.2016.235] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
63 Luo L, Li YX. Pulmonary Langerhans cell histiocytosis and multiple system involvement: A case report. World J Clin Cases 2021; 9(35): 11029-11035 [DOI: 10.12998/wjcc.v9.i35.11029] [Reference Citation Analysis]
64 Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 2018;65. [PMID: 28748614 DOI: 10.1002/pbc.26699] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
65 Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol 2018;78:1035-44. [PMID: 29754885 DOI: 10.1016/j.jaad.2017.05.059] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
66 Paredes SEY, Almeida LY, Trevisan GL, Polanco XBJ, Silveira HA, Vilela Silva E, Segato RAB, da Silva LAB, Chahud F, León JE. Immunohistochemical characterization of immune cell infiltration in paediatric and adult Langerhans cell histiocytosis. Scand J Immunol 2020;92:e12950. [PMID: 32738155 DOI: 10.1111/sji.12950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Arceci RJ, Allen CE, Dunkel IJ, Jacobsen E, Whitlock J, Vassallo R, Morris SR, Portnoy A, Reedy BA, Smith DA, Noble R, Murnane A, Cornfeld M, Rodriguez-Galindo C, Heaney ML, McClain K, Vaiselbuh S. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2017;64. [PMID: 27804235 DOI: 10.1002/pbc.26325] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
68 Xiao Y, van Halteren AGS, Lei X, Borst J, Steenwijk E, de Wit T, Grabowska J, Voogd R, Kemps P, Picarsic J, van den Bos C, Borst J. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis. Blood 2020;136:2188-99. [PMID: 32750121 DOI: 10.1182/blood.2020005209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
69 Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol 2014;27:689-96. [PMID: 25268071 DOI: 10.1097/WCO.0000000000000146] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
70 Lourda M, Olsson-åkefeldt S, Gavhed D, Björnfot S, Clausen N, Hjalmars U, Sabel M, Tazi A, Aricò M, Delprat C, Henter J, Svensson M. Detection of IL-17A-producing peripheral blood monocytes in Langerhans cell histiocytosis patients. Clinical Immunology 2014;153:112-22. [DOI: 10.1016/j.clim.2014.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
71 El Demellawy D, Young JL, de Nanassy J, Chernetsova E, Nasr A. Langerhans cell histiocytosis: a comprehensive review. Pathology 2015;47:294-301. [PMID: 25938350 DOI: 10.1097/PAT.0000000000000256] [Cited by in Crossref: 50] [Cited by in F6Publishing: 11] [Article Influence: 8.3] [Reference Citation Analysis]
72 Collin M, Bigley V, McClain KL, Allen CE. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am 2015;29:825-38. [PMID: 26461145 DOI: 10.1016/j.hoc.2015.06.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
73 Di Liso E, Pennelli N, Lodovichetti G, Ghiotto C, Dei Tos AP, Conte P, Bonanno L. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. Cancer Biol Ther 2015;16:1128-35. [PMID: 26047060 DOI: 10.1080/15384047.2015.1057359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
74 Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013;125:891-900. [PMID: 23435618 DOI: 10.1007/s00401-013-1100-2] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 13.9] [Reference Citation Analysis]
75 Emile JF, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O, Rollins BJ, Donadieu J, Haroche J. Histiocytosis. Lancet 2021;398:157-70. [PMID: 33901419 DOI: 10.1016/S0140-6736(21)00311-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part II. Am J Respir Crit Care Med 2015;192:17-29. [PMID: 25906201 DOI: 10.1164/rccm.201411-2096CI] [Cited by in Crossref: 77] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
77 Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM; Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672-2681. [PMID: 26966089 DOI: 10.1182/blood-2016-01-690636] [Cited by in Crossref: 533] [Cited by in F6Publishing: 448] [Article Influence: 88.8] [Reference Citation Analysis]
78 Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013;133:1624-30. [PMID: 23553055 DOI: 10.1002/ijc.28183] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 8.4] [Reference Citation Analysis]
79 Mitchell JM, Berzins SP, Kannourakis G. A potentially important role for T cells and regulatory T cells in Langerhans cell histiocytosis. Clinical Immunology 2018;194:19-25. [DOI: 10.1016/j.clim.2018.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
80 Pierry C, Caumont C, Blanchard E, Brochet C, Dournes G, Gros A, Bandres T, Verdon S, Marty M, Bégueret H, Merlio J. Assessment of BRAFV600E mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction. Virchows Arch 2018;472:247-58. [DOI: 10.1007/s00428-017-2185-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
81 Berres ML, Allen CE, Merad M. Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases. Adv Immunol 2013;120:127-61. [PMID: 24070383 DOI: 10.1016/B978-0-12-417028-5.00005-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
82 Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017;72:937-945. [PMID: 28689173 DOI: 10.1136/thoraxjnl-2017-210125] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
83 Velz J, Neidert MC, Bozinov O, Grotzer M, Kirschenbaum D, Rushing EJ. Isolated intracerebral Langerhans cell histiocytosis with multifocal lesions. Pediatr Blood Cancer 2017;64. [PMID: 28436595 DOI: 10.1002/pbc.26546] [Reference Citation Analysis]
84 Torre O, Elia D, Caminati A, Harari S. New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26. [PMID: 28954765 DOI: 10.1183/16000617.0042-2017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
85 Shimono J, Miyoshi H, Arakawa F, Sato K, Furuta T, Muto R, Yanagida E, Sasaki Y, Kurita D, Kawamoto K, Nagafuji K, Ohshima K. Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget 2017;8:98723-32. [PMID: 29228722 DOI: 10.18632/oncotarget.21920] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
86 Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014;211:669-83. [PMID: 24638167 DOI: 10.1084/jem.20130977] [Cited by in Crossref: 224] [Cited by in F6Publishing: 196] [Article Influence: 28.0] [Reference Citation Analysis]
87 Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part I. Am J Respir Crit Care Med 2015;191:1354-66. [PMID: 25906089 DOI: 10.1164/rccm.201411-2094CI] [Cited by in Crossref: 92] [Cited by in F6Publishing: 34] [Article Influence: 13.1] [Reference Citation Analysis]
88 Munoz J, Janku F, Cohen PR, Kurzrock R. Erdheim-Chester disease: characteristics and management. Mayo Clin Proc. 2014;89:985-996. [PMID: 24814521 DOI: 10.1016/j.mayocp.2014.01.023] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
89 Olsson Åkefeldt S, Ismail MB, Valentin H, Aricò M, Henter JI, Delprat C. Targeting BCL2 family in human myeloid dendritic cells: a challenge to cure diseases with chronic inflammations associated with bone loss. Clin Dev Immunol 2013;2013:701305. [PMID: 23762095 DOI: 10.1155/2013/701305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
90 Picarsic J, Jaffe R. Pathology of Histiocytic Disorders and Neoplasms and Related Disorders. In: Abla O, Janka G, editors. Histiocytic Disorders. Cham: Springer International Publishing; 2018. pp. 3-50. [DOI: 10.1007/978-3-319-59632-7_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 A Al Hamad M, Albisher HM, Al Saeed WR, Almumtin AT, Allabbad FM, A Shawarby M. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review. BMC Cancer 2019;19:170. [PMID: 30795755 DOI: 10.1186/s12885-019-5372-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
92 Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014;124:3007-15. [PMID: 25202140 DOI: 10.1182/blood-2014-05-577825] [Cited by in Crossref: 245] [Cited by in F6Publishing: 208] [Article Influence: 30.6] [Reference Citation Analysis]
93 Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014;124:483-92. [PMID: 24850756 DOI: 10.1182/blood-2014-03-561381] [Cited by in Crossref: 318] [Cited by in F6Publishing: 265] [Article Influence: 39.8] [Reference Citation Analysis]
94 Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders: Histiocytic Disorders Review. Pediatr Blood Cancer 2014;61:1329-35. [DOI: 10.1002/pbc.25017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
95 Tran G, Huynh TN, Paller AS. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. Journal of the American Academy of Dermatology 2018;78:579-590.e4. [DOI: 10.1016/j.jaad.2017.09.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
96 Chikwava K, Jaffe R. Paediatric histiocytic tumors. Diagnostic Histopathology 2014;20:56-66. [DOI: 10.1016/j.mpdhp.2014.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
97 Matsuoka Y, Iemura Y, Fujimoto M, Shibuya S, Yamada A, Fujii S, Kusaka T, Shindo T, Minamiguchi S, Haga H. Upper Gastrointestinal Langerhans Cell Histiocytosis: A Report of 2 Adult Cases and a Literature Review. Int J Surg Pathol 2021;29:550-6. [PMID: 33034230 DOI: 10.1177/1066896920964566] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Bhatia P, Singh M, Sharma M, Sharma A, Kakkar N, Radhika S, Trehan A, Bansal D. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Blood Cells, Molecules, and Diseases 2020;82:102356. [DOI: 10.1016/j.bcmd.2019.102356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Huo Z, Lu T, Liang Z, Ping F, Shen J, Lu J, Ma W, Zhao D, Zhong D. Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis. Diagn Pathol 2016;11:100. [PMID: 27760550 DOI: 10.1186/s13000-016-0548-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Chen W, Jaffe R, Zhang L, Hill C, Block AM, Sait S, Song B, Liu Y, Cai D. Langerhans Cell Sarcoma Arising from Chronic Lymphocytic Lymphoma/Small Lymphocytic Leukemia: Lineage Analysis and BRAF V600E Mutation Study. N Am J Med Sci 2013;5:386-91. [PMID: 23923114 DOI: 10.4103/1947-2714.114172] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
101 Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, Guglielmi B, Berti A, Lampasona V, von Deimling A, Sabbadini MG, Ferrarini M, Doglioni C, Dagna L. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 2015;74:1596-602. [PMID: 24671772 DOI: 10.1136/annrheumdis-2013-204924] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
102 Nann D, Schneckenburger P, Steinhilber J, Metzler G, Beschorner R, Schwarze CP, Lang P, Handgretinger R, Fend F, Ebinger M, Bonzheim I. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae. Ann Hematol 2019;98:1617-26. [DOI: 10.1007/s00277-019-03678-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
103 Xu X, Nie X, Xiong W, Pan H, Wang W, Yang Q, Liao D, Liu W. [A clinicopathological analysis of 160 cases of adult Langerhans cell histiocytosis]. Zhonghua Xue Ye Xue Za Zhi 2015;36:135-9. [PMID: 25778890 DOI: 10.3760/cma.j.issn.0253-2727.2015.02.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Arceci RJ. Biological and Therapeutic Implications of the BRAF Pathway in Histiocytic Disorders. American Society of Clinical Oncology Educational Book 2014. [DOI: 10.14694/edbook_am.2014.34.e441] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
105 Takei Y, Ueshima C, Kataoka TR, Hirata M, Sugimoto A, Rokutan-Kurata M, Moriyoshi K, Ono K, Murakami I, Iwamoto S, Haga H. Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis. Oncotarget 2017;8:36964-72. [PMID: 28445138 DOI: 10.18632/oncotarget.16936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
106 Baig A, Albrecht S, Corredor AG, Fiset PO, Chen MF. Unique Case of Congenital Langerhans Cell Histiocytosis Presenting as Intrauterine Fetal Demise. Pediatr Dev Pathol 2022;:10935266221078501. [PMID: 35421319 DOI: 10.1177/10935266221078501] [Reference Citation Analysis]
107 Choi SM, Andea AA, Wang M, Behdad A, Shao L, Zhang Y, Lu X, Dittmann D, Castro J, Chen YH, Gao J. KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. Diagn Pathol 2018;13:78. [PMID: 30322385 DOI: 10.1186/s13000-018-0758-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
108 Kemps PG, Zondag TC, Steenwijk EC, Andriessen Q, Borst J, Vloemans S, Roelen DL, Voortman LM, Verdijk RM, van Noesel CJM, Cleven AHG, Hawkins C, Lang V, de Ru AH, Janssen GMC, Haasnoot GW, Franken KLMC, van Eijk R, Solleveld-Westerink N, van Wezel T, Egeler RM, Beishuizen A, van Laar JAM, Abla O, van den Bos C, van Veelen PA, van Halteren AGS. Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. Front Immunol 2019;10:3045. [PMID: 31998317 DOI: 10.3389/fimmu.2019.03045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Ballester LY, Cantu MD, Lim KPH, Sarabia SF, Ferguson LS, Renee Webb C, Allen CE, McClain KL, Mohila CA, Punia JN, Roy A, López-Terrada DH, John Hicks M, Fisher KE. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol 2018;36:307-15. [PMID: 28219109 DOI: 10.1002/hon.2388] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
110 Quispel WT, Stegehuis-Kamp JA, Blijleven L, Santos SJ, Lourda M, van den Bos C, van Halteren AG, Egeler RM. The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome. Oncoimmunology 2016;5:e1084463. [PMID: 28255525 DOI: 10.1080/2162402X.2015.1084463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
111 Guaraldi F, Casar-borota O, Jaffrain-rea M. Hypophysitis. Encyclopedia of Endocrine Diseases. Elsevier; 2019. pp. 325-38. [DOI: 10.1016/b978-0-12-801238-3.64944-9] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Zeng K, Ohshima K, Liu Y, Zhang W, Wang L, Fan L, Li M, Li X, Wang Z, Guo S, Yan Q, Guo Y. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children. Hematol Oncol 2017;35:845-51. [PMID: 27597420 DOI: 10.1002/hon.2344] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
113 Kapatia G, Bhatia P, Singh M, Jain R, Bansal D, Gupta K. Multisystemic Pediatric Langerhans cell histiocytosis: a comprehensive clinico-pathological and BRAF V600E mutation study at autopsy. Autops Case Rep 2020;10:e2020154. [PMID: 33344274 DOI: 10.4322/acr.2020.154] [Reference Citation Analysis]
114 Allen CE, Parsons DW. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program 2015;2015:559-64. [PMID: 26637772 DOI: 10.1182/asheducation-2015.1.559] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
115 Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch 2013;463:623-31. [PMID: 24085553 DOI: 10.1007/s00428-013-1492-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
116 Wu KJ, Li SH, Liao JB, Chiou CC, Wu CS, Chen CC. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study. Biology (Basel) 2021;10:396. [PMID: 34063325 DOI: 10.3390/biology10050396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Néel A, Artifoni M, Donadieu J, Lorillon G, Hamidou M, Tazi A. Histiocytose langerhansienne de l’adulte. La Revue de Médecine Interne 2015;36:658-67. [DOI: 10.1016/j.revmed.2015.04.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
118 Cherian LM, Sasikumar D, Sathyan P, Varghese BE. Langerhans cell histiocytosis: A diagnostic enigma in the oral cavity. J Oral Maxillofac Pathol 2021;25:S27-31. [PMID: 34083966 DOI: 10.4103/jomfp.JOMFP_296_20] [Reference Citation Analysis]
119 Emile JF, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol 2013;31:398. [PMID: 23248255 DOI: 10.1200/JCO.2012.46.9676] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
120 Durham BH. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Seminars in Cell & Developmental Biology 2019;86:62-76. [DOI: 10.1016/j.semcdb.2018.03.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
121 Chilosi M, Facchetti F, Caliò A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, Tomassetti S, Poletti V, Doglioni C. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leukemia & Lymphoma 2014;55:2620-6. [DOI: 10.3109/10428194.2014.887713] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
122 Quispel WT, Steenwijk EC, van Unen V, Santos SJ, Koens L, Mebius R, Egeler RM, van Halteren AG. Tertiary lymphoid structures are confined to patients presenting with unifocal Langerhans Cell Histiocytosis. Oncoimmunology 2016;5:e1164364. [PMID: 27622056 DOI: 10.1080/2162402X.2016.1164364] [Reference Citation Analysis]
123 Han X, Ouyang M, Duan M, Zhang W, Zhu T, Li J, Wang S, Zhou D. The combination of methotrexate and cytosine arabinoside in newly diagnosed adult Langerhans cell histiocytosis: a prospective phase II interventional clinical trial. BMC Cancer 2020;20:433. [PMID: 32423455 DOI: 10.1186/s12885-020-06872-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Peters SM, Pastagia J, Yoon AJ, Philipone EM. Langerhans Cell Histiocytosis Mimicking Periapical Pathology in a 39-year-old Man. Journal of Endodontics 2017;43:1909-14. [DOI: 10.1016/j.joen.2017.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Biller A, Badde S, Nagel A, Neumann JO, Wick W, Hertenstein A, Bendszus M, Sahm F, Benkhedah N, Kleesiek J. Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression. AJNR Am J Neuroradiol 2016;37:66-73. [PMID: 26494691 DOI: 10.3174/ajnr.A4493] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
126 Mckelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA. The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology 2013;45:637-44. [DOI: 10.1097/pat.0000000000000008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
127 Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017;130:167-75. [PMID: 28512190 DOI: 10.1182/blood-2016-12-757823] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
128 Guo Y, Zhou S, Cao Z, Bao Y, Shen L, Yao H. Epstein–Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report. Front Oncol 2022;11:769310. [DOI: 10.3389/fonc.2021.769310] [Reference Citation Analysis]
129 Zeng K, Wang Z, Ohshima K, Liu Y, Zhang W, Wang L, Fan L, Li M, Li X, Wang Y, Yu Z, Yan Q, Guo S, Wei J, Guo Y. BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. Oncoimmunology 2016;5:e1185582. [PMID: 27622040 DOI: 10.1080/2162402X.2016.1185582] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
130 Rizzo FM, Cives M, Simone V, Silvestris F. New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist 2014;19:151-63. [PMID: 24436311 DOI: 10.1634/theoncologist.2013-0341] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
131 Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379:856-868. [PMID: 30157397 DOI: 10.1056/nejmra1607548] [Cited by in Crossref: 125] [Cited by in F6Publishing: 57] [Article Influence: 31.3] [Reference Citation Analysis]
132 Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126:26-35. [PMID: 25827831 DOI: 10.1182/blood-2014-12-569301] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 12.7] [Reference Citation Analysis]
133 Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014;124:1655-8. [PMID: 24982505 DOI: 10.1182/blood-2014-05-577361] [Cited by in Crossref: 223] [Cited by in F6Publishing: 183] [Article Influence: 27.9] [Reference Citation Analysis]
134 Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, Garces JC, Khoury JD, Yin CC. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 2017;30:1367-77. [PMID: 28664935 DOI: 10.1038/modpathol.2017.55] [Cited by in Crossref: 89] [Cited by in F6Publishing: 72] [Article Influence: 17.8] [Reference Citation Analysis]
135 Oishi N, Kondo T, Mochizuki K, Inoue T, Kasai K, Nakazawa T, Mitsumori T, Katoh R. Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses. Hum Pathol 2014;45:1302-5. [PMID: 24703101 DOI: 10.1016/j.humpath.2013.12.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
136 Calandra CR, Bustos A, Falcon F, Arakaki N. Erdheim-Chester disease: atypical presentation of a rare disease. BMJ Case Rep 2017;2017:bcr-2017-220827. [PMID: 29025773 DOI: 10.1136/bcr-2017-220827] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 van Nieuwenhuijze AE, Coghill E, Gray D, Prato S, Metcalf D, Alexander WS, Wicks IP. Transgenic Expression of GM-CSF in T Cells Causes Disseminated Histiocytosis. The American Journal of Pathology 2014;184:184-99. [DOI: 10.1016/j.ajpath.2013.09.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
138 Dimmler A, Geddert H, Werner M, Faller G. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch 2017;470:429-35. [PMID: 28220299 DOI: 10.1007/s00428-017-2092-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. Arch Pediatr 2019;26:301-7. [PMID: 31281037 DOI: 10.1016/j.arcped.2019.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
140 Goto K, Yoshikawa S, Kiyohara Y, Kukita Y, Miura K, Oishi T. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report. J Cutan Pathol 2021. [PMID: 34792818 DOI: 10.1111/cup.14171] [Reference Citation Analysis]
141 Go H, Jeon YK, Huh J, Choi SJ, Choi Y, Cha HJ, Kim H, Park G, Min S, Kim JE. Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 2014;65:261-72. [DOI: 10.1111/his.12416] [Cited by in Crossref: 145] [Cited by in F6Publishing: 119] [Article Influence: 18.1] [Reference Citation Analysis]
142 Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I, Barth TF, Beer AJ, Möller P, Gottstein M, Viardot A, Lennerz JK. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 2014;5:4060-70. [PMID: 24938183 DOI: 10.18632/oncotarget.2061] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
143 West JA, Olsen SL, Mitchell JM, Priddle RE, Luke JM, Akefeldt SO, Henter JI, Turville C, Kannourakis G. Polyclonal T-cells express CD1a in Langerhans cell histiocytosis (LCH) lesions. PLoS One 2014;9:e109586. [PMID: 25343480 DOI: 10.1371/journal.pone.0109586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]